| Familial Hypercholesterolemia |
| Geno
|
Mag
|
Summary
|
| (A;G)
|
5
|
Familial Hypercholesterolemia
|
| (C;G)
|
5
|
Familial Hypercholesterolemia
|
| (G;G)
|
0
|
common in complete genomics
|
| (G;T)
|
5
|
Familial Hypercholesterolemia
|
| (T;T)
|
3
|
|
This is a genotype with recommended actions if clinically confirmed. In brief:
- FH (familial hypercholesterolemia) is characterized by high low-density lipoprotein cholesterol (LDL-C) and increased risk of premature coronary artery disease; untreated LDL-C concentrations are typically in the range of 190-350 mg/dL.
- These raised LDL-C concentrations are likely to be present during childhood and may lead to early development of atherosclerosis and coronary heart disease (CHD) if left untreated.
- Patients should consider lifelong, high-intensity statin therapy beginning in childhood (age 8). Statin use in FH patients may reduce CHD risk by 76%.
- Consider taking aspirin daily.
- High blood pressure and diabetes are additional CHD risk factors and should be treated aggressively in FH individuals.
- Monitor blood pressure every 6 - 12 weeks and lipid levels at least annually.
- FH patients should avoid additional risk factors for CHD including smoking, physical inactivity, diets high in saturated fats and cholesterol, unhealthy body weight, and excessive alcohol consumption.
- Consider LDL-C or genetic testing of family members.
The full ClinGen Actionability report about Familial Hypercholesterolemia (HeFH) can be found here.
Genetic counseling may be available to you through your health-care network. In the US, genetic counselors may be found via this webpage of the National Society of Genetic Counselors.
